(UroToday.com) In this presentation, Dr. Brian Rini presented 42-month follow-up data from the KEYNOTE-426 trial of pembrolizumab in combination with axitinib as first-line therapy for clear cell renal cell carcinoma (ccRCC). The first interim analysis of this combination, published in 20191 showed a statistically significant improvement in overall survival and progression-free survival relative to sunitinib. Subsequent follow-up at a median of 30.6 months confirmed these findings. For this presentation, Dr. Rini presented data from a median follow-up of 42.8 months, with a minimum follow-up of 35.6 months.

X